Asivatrep cream safe, effective for atopic dermatitis

Asivatrep cream improves clinical signs and symptoms of atopic dermatitis (AD) without causing worrying adverse events, reports a recent study.

Researchers conducted a phase 3 double-blinded, vehicle-controlled study, enrolling 237 patients with mild to moderate AD. Eighty were given a vehicle cream, while the remaining 157 received the active 1.0% asivatrep cream intervention. The trial lasted for 8 weeks during which time creams were applied twice daily.

After 8 weeks, the primary outcome of an Investigator’s Global Assessment (IGA) score of 0 or 1 was significantly more common in the active intervention vs control group (36.0 percent vs 12.8 percent; p<0.001). Similarly, asivatrep-treated patients were more likely to see a ≥2-point improvement on the IGA from baseline scores (20.3 percent vs 7.7 percent; p=0.01).

Moreover, the asivatrep cream led to a 44.3-percent drop in the Eczema Area and Severity Index (EASI) scores, significantly greater than the 21.4-percent decrease in vehicle controls (p<0.001). The proportion of patients who saw at least a 50-percent, 75-percent, and 90-percent improvements in EASI were likewise significantly higher in the asivatrep arm.

Asivatrep also significantly improved pruritus relative to vehicle control, as quantified by visual analogue scale scores (–2.3 vs –1.5; p=0.02).

Of note, the asivatrep cream was well-tolerated, leading to no related clinically significant application site adverse reactions.

“Treatment with asivatrep cream resulted in marked and sustained relief of signs and pruritus associated with AD in adolescents and adults, along with an acceptable safety profile,” the researchers said. “The results show that asivatrep cream may be a novel and effective topical medication for patients with AD.”